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Innervation of the gut is segmentally lost in Hirschsprung disease (HSCR), a consequence of cell-autonomous and non-autonomous de-
fects in enteric neuronal cell differentiation, proliferation, migration, or survival. Rare, high-penetrance coding variants and common,
low-penetrance non-coding variants in 13 genes are known to underlie HSCR risk, with themost frequent variants in the ret proto-onco-
gene (RET). We used a genome-wide association (220 trios) and replication (429 trios) study to reveal a second non-coding variant distal
to RET and a non-coding allele on chromosome 7 within the class 3 Semaphorin gene cluster. Analysis in Retwild-type and Ret-null mice
demonstrates specific expression of Sema3a, Sema3c, and Sema3d in the enteric nervous system (ENS). In zebrafish embryos, sema3
knockdowns show reduction of migratory ENS precursors with complete ablation under conjoint ret loss of function. Seven candidate
receptors of Sema3 proteins are also expressed within the mouse ENS and their expression is also lost in the ENS of Ret-null embryos.
Sequencing of SEMA3A, SEMA3C, and SEMA3D in 254 HSCR-affected subjects followed by in silico protein structure modeling and func-
tional analyses identified five disease-associated alleles with loss-of-function defects in semaphorin dimerization and binding to their
cognate neuropilin and plexin receptors. Thus, semaphorin 3C/3D signaling is an evolutionarily conserved regulator of ENS develop-
ment whose dys-regulation is a cause of enteric aganglionosis.Introduction
The origins of the enteric nervous system (ENS) from the
neural crest lineage are hypothesized to be an early evolu-
tionary innovation, present in echinoderms and all chor-
dates, antedating the central nervous system (CNS).1 Often
referred to as the ‘‘second brain,’’ the ENS exhibits a simi-
larly wide array of neuronal and glial cells as the CNS
and responds to the same neurotransmitters. It is, however,
quite distinct from, and can mediate reflexes indepen-
dently of, the CNS. Physiologically, the ENS controls the
critical processes of enzyme secretion, ion transport associ-
ated with secretion and absorption, blood flow, and peri-
stalsis in the gastrointestinal (GI) tract. These functions
are severely compromised in a diverse group of develop-
mental and acquired pathologies including Hirschsprung
disease (MIM 142623, 600155, 613711, 613712, 600156,
606874, 606875, 608462, and 611644), hypoganglionosis,
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The Amchronic intestinal pseudo-obstruction (MIM 300048),
and irritable bowel syndrome. These disorders have largely
been recognized within the past 60 years and their genetic
pathophysiology remains poorly understood.
The most common disorder of the ENS at birth is Hirsch-
sprung disease (HSCR), also known as congenital aganglio-
nosis. It is characterized by a lack of enteric ganglia in the
myenteric and submucosal plexuses involving varying
lengths of the colon, resulting from incomplete rostral-
to-caudal enteric colonization.1,2 With a population inci-
dence of ~15/100,000 live births in newborns of European
ancestry and twice that among Asian newborns, this neu-
rodevelopmental birth defect has classical features of a
multifactorial genetic disorder: high heritability (>80%),
sex difference in incidence (4.0 male:female), high sibling
recurrence risk (250-fold greater than the population), and
non-Mendelian inheritance in families.2 HSCR displays
a variable phenotype with recurrence risk depending on
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and segment length of aganglionosis and is classified
as short Hirschsprung (S-HSCR), long Hirschsprung
(L-HSCR), or total colonic aganglionosis (TCA) based on
the length of the aganglionosis. The reasons for the high
heritability and phenotypic variation remain enigmatic,
although gene discovery has clarified some genotype-
phenotype correlations. Genetic studies have identi-
fied rare high-penetrance mutations in 12 genes (RET
[MIM 164761], GDNF [MIM 600837], NRTN [MIM
602018], SOX10 [MIM 602229], EDNRB [MIM 131244],
EDN3 [MIM 131242], ECE1 [MIM 600423], ZEB2 [MIM
605802], PHOX2B [MIM 603851], KIAA1279 [MIM
609367], TCF4 [MIM 602272], and L1CAM [MIM
308840]), cumulatively explaining only a modest number
of cases (<10%) and often involving syndromic forms.2,3
Surprisingly, significantly greater phenotypic variation is
explained by two common low-penetrance non-coding
variants at RET (rs2435357)4 and NRG1 (MIM 142445)
(rs4541858),5 respectively. Of these, rs2435357 disrupts
function of a GI-tract-specific enhancer in RET intron 1
through abrogation of SOX10 binding, thereby reducing
RET expression.6
HSCR is a model complex disease that has provided
numerous insights into the nature of non-Mendelian in-
heritance. In particular, the RET enhancer polymorphism
not only confers significant biological susceptibility to
the most common form of HSCR, S-HSCR, but also ex-
plains three phenotypic features of the disorder: (1) vari-
able risk of disease as a function of gender, familiality,
and segment length of aganglionosis, (2) allelic interaction
with rare coding mutations, and (3) association of HSCR
with other clinical syndromes, including Down syndrome,
through non-allelic interactions.6–8 These are surprisingly
pervasive genetic effects for a birth defect that was effec-
tively lethal ~60 years ago, prior to surgical treatment,
and suggests the effects of natural selection on the
enhancer. These results, and similar genetic properties of
a NRG1 common variant in Chinese HSCR-affected sub-
jects,5 prompted us to search broadly for additional poly-
morphisms that could further explain HSCR susceptibility
and its associations with the common isolated forms.
Here we demonstrate, through human, mouse, and ze-
brafish analyses, that class 3 Semaphorins are one suchma-
jor susceptibility factor in HSCR because (1) a common
non-coding variant enhances susceptibility in humans,
(2) rare deleterious variants in SEMA3C (MIM 602645)
and SEMA3D (MIM 609907) are more frequent than ex-
pected in individuals with HSCR, (3) these variants have
in vitro loss-of-function defects in semaphorin dimeriza-
tion and binding to their cognate neuropilin and plexin re-
ceptors, (4) genetic interactions between loss of function of
class 3 Semaphorins and Ret lead to aganglionosis in zebra-
fish, and (5) all seven receptors of Sema3 proteins are ex-
pressed within the embryonicmouse ENS and their expres-
sion is lost in the ENS of Ret-null mouse mutant embryos.
Thus, class 3 Semaphorin signaling is a critical functional
module in ENS development, conserved from zebrafish582 The American Journal of Human Genetics 96, 581–596, April 2, 2to humans. These proteins act on RET-positive ENS neu-
rons and uncover an additional axis of genetic defects in
HSCR epistatic to RET.Material and Methods
Affected and Control Samples
Affected personswere classified by segment length of aganglionosis
into three classes: S-HSCR (aganglionosis up to the upper sigmoid
colon), L-HSCR (aganglionosis up to the splenic flexure), and TCA
(total colonic aganglionosis). We used a primary GWAS sample of
220 trios comprising one affected individual and both of his/her
parents from the USA, Italy, the Netherlands, Spain, and France,
and a replication sample of 429 trios from the same 5 countries rep-
resenting the phenotypic spectrum of HSCR observed in the popu-
lationandshowingvariationbygender, segment length, familiality,
presence of additional anomalies, and genomic DNA availability.
The primary sample was composed primarily of S-HSCR-affected
subjects: 180/40 were male/female; 214/3/0/3 were S-HSCR/L-
HSCR/TCA/unknown segment length; 196/24were simplex/multi-
plex; and 3 probands had additional anomalies (one with Down
syndrome [MIM 190685] and two with Shah-Waardenburg
syndrome2 [MIM 277580, 613265, and 613266]). The replication
sample was indifferent to segment length (287/141/1 were male/
female/indeterminate; 135/90/83/121 were S-HSCR/L-HSCR/TCA/
unknown segment length; 298/129/2 were simplex/multiplex/un-
known). To identify sequence variants, we studied a phenotypically
broader group of 254 subjects consisting of 205, 34, 14, and 1 indi-
viduals from the USA, Italy, the Netherlands, and France, respec-
tively, to include the diversity of segment length of aganglionosis
(95 S-HSCR, 71 L-HSCR, 85 TCA, and 3 unknown segment [UN]),
sex (173/81 were male/female), familiality (168/86 were simplex/
familial), and presence of additional anomalies (236/18 were iso-
lated/had additional anomalies). All study individuals self-identi-
fied as being of European ancestry. Details of the samples are in
Table S1. In addition, we genotyped 1,054 samples representing
control subjects across five continents from the CEPH Human
Genome Diversity Panel.9 Subject ascertainment was conducted
with written informed consent approved by the Institutional Re-
view Boards of Johns Hopkins University School of Medicine and
all participating institutions.SNP Genotyping
All members of trios were genotyped on the Affymetrix 500K plat-
form, using 250 ng of genomic DNA digested by the restriction en-
zymes StyI and NspI, hybridized to arrays, and genotypes called by
the CRLMM algorithm:10 100 trios each were genotyped with the
StyI or NspI arrays and 33 trios on both StyI and NspI arrays to
allow improved imputation. For quality control, we set the criteria
for SNPs and trios to have genotyping call rates > 80%, allele fre-
quency> 5%, Hardy-Weinberg p value> 105, and%2Mendelian
errors per family. After genotypes were cleaned, we dropped a total
of 13 trios (1 due to unsuccessful PCR amplification; 2 owing to
poor genotyping call rates; 10 due to >2 Mendelian inconsis-
tencies) to analyze 220 trios (Table S1). The genotyped data on
each trio varied between 250K and 500K markers that we first
imputed to a common set of 356,308 SNPs above 5% allele fre-
quency and reliably imputed (r2 > 0.3) across all samples by using
the reference data from the HapMap CEU sample11 and the com-
puter program BEAGLE.12015
Genotypes on individual SNPs, either for replication or for
estimating the global control distribution, were obtained via a fluo-
rogenic 50 nuclease end-point assay on 10 ng of genomic DNA as
template and evaluated on an ABI 7900 (Taqman, Life Technolo-
gies). Specific genotypes on the three riskmarkers (rs2435357,Assay
ID: C__16017524_10; rs2506030, Assay ID: C__26742714_10;
rs12707682, Assay ID: C__30936238_10) were obtained with
TaqMan Human Pre-Designed Assays (Applied Biosystems). PCR
amplification was performed with PerfeCTa qPCR SuperMix, ROX
(Cat# 95051-100, Quanta BioSciences) on 10 ng DNA templates.
Enzyme activation and the initial denaturation cycle was at 95C
for 10 min, followed by 40 cycles of 92C for 15 s and 60C for
1 min and a final extension at 60C for 10 min. Plates were read
on an ABI PRISM 7900 sequence detection system and the data
analyzed with SDS 2.2 software (Applied Biosystems). All SNPs had
call rates greater than 98% (rs2435357, rs2506030, rs12707682
had data completeness of 98.4%, 98.0%, and 99.2%, respectively).
DNA Sequencing
For DNA sequencing, genomic DNA was used as a template for
PCR amplification of all coding exons in SEMA3A, SEMA3C, and
SEMA3D (Table S3). Amplification products were visualized on 2%
agarose gels by electrophoresis and purifiedwith QIAquick PCR pu-
rification kit (QIAGEN). Subsequently, all amplicons derived from
an individual’s DNA sample were pooled in a length-weighted
equi-volume ratio before library preparation, emPCR, and pyrose-
quencing on the 454 GS Junior platform as described.13
Statistical Analysis
Genome-wide association studies (GWASs) were first performed on
220 trios comprising the primary sample and 356,308 SNPs by
comparing case subjects with pseudo-controls (consisting of the
twoparental alleles not transmitted to the affected) via theArmitage
trend test.14 We used an initial threshold of 0.0001 to choose 10
SNPs for replication in 429 additional trios and a final genome-
wide statistical threshold of 1.4 3 107. For final results, we used
HapMap11 reference data to impute the genotypes of all individuals
in >2.5 million SNPs in the primary sample. When necessary, LD
blocks and r2 values were estimated with the HapMap CEU data
(r28) via the Tagger program in Haploview 4.2.15 Associated SNPs
were furtherconfirmed in the1000Genomesdatavia theSNPAnno-
tation and Proxy Search (SNAP) tool.16 The data were also analyzed
with the TDT (transmission disequilibrium test) by a maximum
likelihoodmethod toestimate the risk-allele transmission frequency
(t) and an allelic odds ratio.6 Penetrance values were estimated
as described with the following parameters: incidence of 15 in
100,000 livebirths;male:female sex ratioof4.0; 80:10:10 for propor-
tions of S-HSCR, L-HSCR, and TCA probands; and frequency of
multiplex cases as 25%.6
Gene Expression Assays
Gene expression in human and mouse tissues and across
developmental time points was analyzed with assays from Applied
Biosystems and real-time PCR analysis on cDNA panels from
Clontech.
RNA In Situ Hybridization
Mouse
In analyses of mouse embryos, section or whole-mount RNA
in situ hybridization was performed as described.17,18 The relevant
antisense probes were generated as described18 via probe templatesThe Amprovided by Dr. David Ginty (Johns Hopkins University, Balti-
more, MD): Sema3A, cut with EcoRI, polymerized with T7;
Sema3C, KpnI, T7; and Sema3D, XhoI, T3; Sema3E, SalI, T7. Addi-
tional templates were PlexinA1, cut with BamHI, polymerized
with T3; PlexinA3, Xba, T3; Plexin A2, XhoI, T3; PlexinA4, EcoRV,
T3 (Sakai and Halloran19) (the last two kindly provided by Kevin
Mitchell); PlexinD1, NotI, SP6 (Banu et al.20) (kindly provided
by Jeffrey Macklis); Neuropilin1, SacI, T3 (Sakai and Halloran19);
and Neuropilin2, XhoI, T3 (Huber et al.21). Wild-type embryonic
and postnatal tissues were isolated from Parkes (outbred) mice.
Mice carrying the null Retk/k mutation and their genotyping
have been described earlier.22,23 The day of the vaginal plug was
considered to be E0.5. All animal studies were performed under
protocols approved by the MRC National Institute for Medical
Research Animal Care and Use Committee (UK) and the Johns
Hopkins Institutional Animal Care and Use Committee.
Zebrafish
The translation-blocking morpholinos for sema3aa and sema3ab
have been described previously.24 The translation-blocking mor-
pholino for sema3c had sequence 50-AAAGAGCATGAATGCTGGA
GACGCT-30, and its control mismatch oligo had sequence 50-AAA
GACCATCAATCCTGCACACGCT-30 (mismatched residues under-
lined). The splice-blocking morpholino for sema3d has been previ-
ously described (3DMO2).25 The translation blocking morpholino
for sema3e had sequence 50-TGAAAGTCCACACACCCCACGC
CAT-30. The translation-blocking morpholino for ret is as
described.26 All morpholinos were designed and purchased from
Gene Tools. Zebrafish embryos were fixed at 4, 5, or 6 dpf in 4%
paraformaldehyde/13 fix buffer (4% sucrose, 0.15 mM CaCl2 in
0.1 M PO4 buffer) for 2 hr. They were then quickly rinsed and sub-
sequently washed three times for 10 min per wash with 13 PBTx
(13 PBS with 0.5% Triton X-100). Three additional water washes,
1 hr per wash, were done for 4 and 5 dpf fish, and six additional
water washes, 1 hr per wash, were done for 6 dpf fish. Embryos
were pre-incubated in blocking solution (13 PBS, 10% heat inacti-
vated goat serum, 0.5% Triton X-100, 2 mg/ml BSA, 1% DMSO,
0.02% NaN3) for 1 hr at room temperature and then incubated
overnight in blocking solution containing a 1:100 dilution of a
0.2 mg/ml monoclonal (16A11) anti-HuC antibody from Invitro-
gen (catalog #A-21271). They were then quickly rinsed and subse-
quently washed three times for 30 min per wash with 13 PBTx,
followed by incubation for 2 hr in blocking solution with
1:1,000 dilution of the Alexa Fluor 568-conjugated F(ab’)2 frag-
ment of goat anti-mouse IgG (HþL) secondary antibody from
Invitrogen (catalog #A11019).Determination and Refinement of SEMA3C/D 3D
Structures
SEMA3C and SEMA3D homology models were constructed
via MODELER27 by employing one of the monomers from the
SEMA3A dimer complex (PDB: 4GZ8: A)28 as template. Ten homol-
ogy models were constructed for both SEMA3C and SEMA3D and
the model with the best DOPE29 scores were selected for further
studies. Selected SEMA3C/Dmonomer structures were then dupli-
cated and superimposed on individual chains of the SEMA3A
dimer to provide starting structures for docking calculations.
One thousand models were generated for both SEMA3C and
SEMA3D via RosettaDock30 and the structures with the best inter-
face score, based on the RosettaDock energy function, were
selected. Similarly, the crystal structure of Plexin A2-Semaphorin
3A-Neuropilin-1 (PDB: 4GZA)28 was used as the starting templateerican Journal of Human Genetics 96, 581–596, April 2, 2015 583
for the generation of Semaphorin-Neuropilin-1 and Semaphorin-
Plexin A2 complexes. SEMA3C and SEMA3D models were super-
imposed on the SEMA3A chain in the complex and employed as
the starting structures for RosettaDock calculations. The generated
models for Semaphorin-Semaphorin, Semaphorin-Neuropilin,
and Semaphorin-Plexin complexes were then used for calculation
of the effects of individual substitutions on stability and binding.
In residue substitution calculations by Rosetta, the desired side
chain was mutated and optimized by discrete sampling of the res-
idue side-chain conformational space using a backbone-depen-
dent rotamer library.31 The wild-type and variant structures were
scored with the standard Rosetta energy function and the differ-
ence in their scores (DGvariant – DGwild-type) was noted as the
free energy change (DDG) of a substitution. Protein-protein
interfaces in the variant complexes were then optimized by line
minimization of the rigid-body orientation of the complex pro-
teins via the RosettaDock score function. Interface scores (I_sc ¼
Ecomplex –
P
Epartners) of the mutant complexes were then evalu-
ated and compared to the interface scores of the wild-type com-
plexes (DI_sc¼ I_scvariant – I_scwild-type) for prediction of a substitu-
tion’s effect on binding.Site-Directed Mutagenesis and Ligand Preparation
TwoSEMA3Cvariantswere recreatedbysite-directedmutagenesisas
an N-terminal AP-tagged mouse Sema3c cDNA in a pCMV-driven
pcDNA1 vector. This construct lacks the native signal sequence of
Sema3c and the resulting alkaline phosphatase (AP) fusion protein
can be expressed as a secreted ligand and used directly as a highly
sensitive affinity agent. Similarly, three SEMA3D variants were
introduced by site-directed mutagenesis into a mouse Sema3d
cDNA cloned into the 50 BspEI/30 XbaI site of a pAPtag-4 vector.
The native signal peptide of Sema3d was removed. Mutant strand
synthesis reactionswere set up according tomanufacturers’ instruc-
tions. PCRproductsweredigestedwithDpnI (Agilent Technologies)
and transformed into MC1061/P3 competent E. coli (Cat #: C663-
03, Invitrogen). Clones harboring the desired single-nucleotide
change were verified by DNA sequencing. Each mutant-encoding
vectorwas transiently introduced intoHEK293TcellswithLipofect-
amine 2000 (Life Technologies). Conditioned medium was har-
vested72hrafter transfectionand ligandconcentrationdetermined
as described.32,33 Equal amounts of AP-Sema-transfected HEK293T
cell supernatant was concentrated (with Amicon Ultra-0.5 ml 3K
column fromMillipore) and subjected to7.5%SDS-PAGE for immu-
noblotting with Anti-Placental Alkaline Phosphatase, PLAP (Cat #:
13-2355, American Research Products).COS7 Cell Binding Assays
AP-ligand binding assays were performed as described.34 In brief,
mouse Neuropilin1 (Nrp1) or Neuropilin2 (Nrp2) constructs were
overexpressed in COS-7 cells after transfection via Lipofectamine
2000. Forty-eight hours after transfection, cells were incubated
with various AP-tagged Sema3C or Sema3D (wild-type or mutant
fusion protein) containing media for examining receptor binding
capacity. Bound AP activity values were normalized for the fusion
protein used and reported as fold change relative to wild-type
constructs.Plotting Routines
Results of GWAS analyses, displayed as Manhattan and QQ
plots, used software and public genomic data via available
methods.11,35,36584 The American Journal of Human Genetics 96, 581–596, April 2, 2Results
A Family-Based Genome-wide Association Study
We studied 220 affected child-parent trios of European
ancestry with S-HSCR, because the previously identified
RET andNRG1 common variants had the largest genetic ef-
fect in this category and they are the commonest form of
aganglionosis (~80% of cases).2 The affected offspring
had a sex ratio of 4.5 and had HSCR as the sole phenotype
in all but three cases (Table S1). We genotyped a maximum
of 500,000 SNPs on an Affymetrix platform and excluded
all markers with minor allele frequency < 5%, Hardy-
Weinberg p value < 105, data completeness < 80%,
and>2Mendelian errors. The resulting 356,308 high-qual-
ity SNPs common to all samples through imputation had
frequencies similar to HapMap11 reference data and were
analyzed for allelic association using both the case versus
pseudo-control14 and the transmission disequilibrium
tests.6 The aim was to identify SNPs that exceed a liberal
threshold significance (p ¼ 104) for replication. We iden-
tified nine SNPs at seven independent loci: rs12076751
(chr 1), rs10930239 (chr 2), rs839232 (chr 3), rs9405709
(chr 6), rs1228871, rs12707682, and rs11766001 (chr 7),
rs2506030 (chr 10), and rs11073865 (chr 15). We also ob-
tained positive signals at the NRG1 intronic variant
rs4541858 and at numerous SNPs in high linkage disequi-
librium (LD) with the common enhancer polymorphism
(rs2435357). To replicate the loci, we genotyped a total of
11 SNPs in an independent set of 429 trios of European
ancestry representing all segment lengths: the 9 variants
listed above plus rs4541858 and rs2435357 (that was not
on the array nor could be imputed) (Table S1). We declared
replication if p < 0.005 (corrected for ten tests not
including rs2435357). Next, we used HapMap11 reference
data to impute the genotypes of all individuals in >2.5
million SNPs in the primary sample (Figure S1).
The replication study yielded three statistically signifi-
cant associations in addition to the well-established func-
tional allele at rs2435357 (p¼5.7331034) (Table 1). These
associations identify a second chromosome 10q peri-
centromeric locus (rs2506030: replication p¼ 2.023 104,
total p¼ 4.443 1015) (Figure 1A) and two variants at chro-
mosome 7q: rs12707682 (replication p¼ 1.383 104, total
p ¼ 9.16 3 1010) and rs11766001 (replication p ¼ 4.24 3
104, total p ¼ 5.11 3 109) (Figure 1C). SNP rs4541858,
located in intron 1 of NRG1 and in complete LD with the
Asian-associated NRG1 SNP rs7835688, displayed signifi-
cant association in the primary screen (p ¼ 2.94 3 105),
in viewof its earlier discovery butwas borderline significant
in the replication (p¼0.041) andnot significant in the total
sample by genome-wide criteria (p ¼ 3.25 3 105). Inspec-
tion of the QQ plot of the imputed GWAS results
(Figure S1) suggests that once the effects of the RET and
7q loci are accounted for, no other common polymor-
phisms are evident. Comparison of marker alleles show
higher frequencies in cases in the primary GWAS screen
than in the replication sample (Table 1). Because these015













p pCase Control Case Control
rs11766001 7: 84,145,202 SEMA3 C/A 0.34 0.18 9.35 3 107 0.24 0.17 4.24 3 104 5.11 3 109
rs12707682 7: 84,443,356 SEMA3 C/T 0.39 0.23 3.52 3 107 0.32 0.24 1.38 3 104 9.16 3 1010
rs4541858 8: 32,410,309 NRG1 G/A 0.56 0.42 2.94 3 105 0.48 0.42 4.11 3 102 3.25 3 105
rs2506030 10: 43,447,847 RET G/A 0.63 0.35 2.78 3 1015 0.55 0.45 2.02 3 104 4.44 3 1015
rs2435357 10: 43,582,056 RET T/C 0.67 0.21 2.83 3 1033 0.55 0.22 5.73 3 1034 5.21 3 1064
For each locus, the SNP, genomic location (chromosome, position [hg19]), risk/non-risk allele, case and pseudo-control allele frequency, and association p value is
shown for the primary (220 S-HSCR trios) and replication (429 any segment HSCR trios) samples; only p values for the combined sample is given.two samples differ in the composition of gender, segment
length, and familiality of cases, and prior associations
were stronger in S-HSCR-affected simplex males than in
other forms,6 it is unknownwhether these small frequency
differences are from the ‘‘winner’s curse’’ or the composi-
tion of cases.
Independent, Common Susceptibility Alleles at RET
and SEMA3
SNP rs2506030 with risk allele G (non-risk allele A) has an
allele frequency of 0.63 in cases against a background allele
frequency of 0.35 in theprimaryGWAS sample, a difference
that is statistically significant (p ¼ 2.78 3 1015); in the
replication sample these frequencies are 0.55 and 0.45,
respectively, a smaller yet significant difference between
case and control subjects (p ¼ 2.02 3 104) (Table 1). In
the combined sample, the genotype data reveal the fre-
quency of the risk allele to be 0.58 in case versus 0.41 in con-
trol subjects corresponding to an odds ratio of 2.0; the pop-
ulation penetrance of the three genotypes varies 3.8-fold
(1.13105 to 4.23104) (Table 2). This susceptibility allele
is largely independent of the known RET enhancer variant
as shown by the fact that the correlation between them is
small (r2 ¼ 0.23) in our control chromosomes as well as in
the HapMap CEU sample. Nevertheless, rs2506030 has a
large allelic effect (odds ratio ¼ 2.0) even in relation to
rs2435357 (odds ratio ¼ 5.3) and, indeed, most complex
traits. We have previously shown that 8%, 66%, and 13%
of all HSCR-affected probands have a rare RET coding
variant only, the rs2435357 risk variant only, or both; in
addition, up to 5% of all probands carry a deletion within
RET.6 Therefore, with the detection of rs2506030, <5% of
HSCR-affected case subjects are free of any known risk
variant, leading us to conclude that RET mutations are
necessary for HSCR in the vastmajority of affected persons.
rs2506030 is located in non-coding DNA ~125 kb
upstream of RET, proximal to BMS1 (MIM 611448), a
ribosome biogenesis protein (Figure 1A). The variant does
not lie within a gene nor do gene annotations of this
region lead to suspicion of any gene beyond RET. Thus,
rs2506030, or SNPs in high LD with it, is a second poly-The Ammorphic potential regulatory element of RET. We searched
this genomic locus for all known highly associated (r2 R
0.8) common polymorphisms (>10%) and annotated
this 15.4 kb region for sequence conservation and candi-
date fetal intestinal enhancers based on H3K4me1 and
H3K27ac histone modifications and DNase I hypersensi-
tive sites (Figure 1B). Only rs2506030 directly overlapped
a H3K4me1 and a H3K27ac mark but was not evolution-
arily conserved except in primates. We hypothesize that
this polymorphism is likely to disrupt an enhancer of RET.
The second association was evident at chromosome
7q21.11 at rs12707682 (replication p ¼ 1.38 3 104) and
rs11766001 (replication p¼ 4.243 104). The twomarkers
are spatially distinct in a region of very high LD and the
SNPs are highly correlated with one another (r2 ¼ 0.50);
we do not consider rs11766001 to be an independent
signal (Figure 1C). The peak SNP rs12707682 has risk allele
C (non-risk allele T) and an allele frequency of 0.39 in case
subjects and 0.23 in control subjects in the primary GWAS
sample, a difference that is statistically significant given
our screening threshold (p ¼ 3.52 3 107) (Table 1). In
the replication sample, the genotype data reveal the fre-
quency of the risk allele to be 0.32 in case subjects versus
0.24 in control subjects corresponding to an odds ratio of
1.8; the population penetrance of the three genotypes
varies 3.1-fold (1.4 3 105 to 4.3 3 104) (Table 2). This
region gained interest because it contained a family of
intriguing candidate genes, four related members of class
3 Semaphorins that are critical to neuronal develop-
ment.37 The sentinel SNP was located between the
genes encoding Semaphorin 3A (SEMA3A [MIM 603961])
and 3D (SEMA3D [MIM 609907]), ~1.16 mb upstream of
Semaphorin 3E (SEMA3E [MIM 608116]), and at a consid-
erable distance of ~3.89 Mb upstream of Semaphorin 3C
(SEMA3C [MIM 602645]).
We searched this large candidate genomic region for one
or more variants that might explain the association. We
identified a 139 kb segment that contained all common
polymorphisms (>10%) highly associated (r2 > 0.8) with
rs12707682 and annotated this region for sequence con-
servation and candidate fetal intestinal enhancers basederican Journal of Human Genetics 96, 581–596, April 2, 2015 585
Figure 1. Genetic Associations at the RET and SEMA3 Loci
(A) Black dots representlog10 p values (y axis, left) for all SNPs studied plotted against their hg19 genomic location (with recombination
rate plotted in light blue (y axis, right). The leading variants in the combined data are highlighted in red. RET and additional genes near
the peak SNP rs2506030 are depicted at the bottom of the windowwith arrows indicating the direction of transcription; the highest peak
is at the previously described enhancer variant rs2435357; the new peak is at rs2506030.
(B) The 15.4 kb genomic region of high (r2> 0.8) linkage disequilibrium around SNP rs2506030 showing locations of all known common
(>10%) SNPs, sequence conservation, and enhancer marks from human male fetal gut (DNase I hypersensitive sites, H3K4me1,
H3K27ac).
(C) The four SEMA3 genes near the peak SNPs rs12707682 and rs11766001, with legend as in (A).
(D) The 219 kb genomic region of high (r2 > 0.8) linkage disequilibrium around rs12707682 is depicted, with legend as in (A).on H3K4me1 and H3K27ac histone modifications and
DNase I hypersensitive sites (Figure 1D). We did not detect
any overlap between these polymorphisms and any regula-
tory feature despite our suspicion that rs12707682 or its
surrogates probably disrupt function of a non-coding regu-
latory element in the GI tract. Fine mapping of this region
in additional cases and mapping regulatory elements at
other GI developmental time-points might be required
for an answer.
The risk alleles at RET (rs2435357 and rs2506030) and at
SEMA3 (rs12707682) are common in the general European
ancestry population with allele frequencies of 24%,
39%, and 26%, respectively, in the HapMap CEU sam-
ples6,11 and with odds ratios of 5.3, 2.0, and 1.8, respec-
tively, and therefore have significant impact on disease
risk. rs2435357 is significantly associated with the more
common attributes of HSCR: male gender, short segment
length, and simplex familiality;6 this is also the case for
the NRG1 variant in Asians.5 Consequently, we asked586 The American Journal of Human Genetics 96, 581–596, April 2, 2whether the same was true for the rs2506030 and
rs12707682 variants. These analyses demonstrate statisti-
cally significant differences in risk according to gender
(higher in males: 3.51 3 104), segment length (higher
in S-HSCR: 1.213 106), and familiality (higher in simplex
cases: 1.51 3 102) for RET rs2506030 but no differences
for SEMA3 rs12707682 (p > 0.42) (Table S2). These differ-
ences can be translated into estimates of population-level
penetrance by genotype to show that the rs2506030
effect is largely through risk-allele homozygotes, whereas
non-significant rs12707682 risks are larger for both
homozygotes and heterozygotes. In other words, the
genotype-phenotype correlation between HSCR is so far
demonstrable only for both RET risk polymorphisms.
Functions of Class 3 Semaphorins in Mice and
Zebrafish
The C risk allele at rs12707682 is widespread in humanity:
we genotyped control samples from the Human Genome015
Table 2. Population-Level Genotype Penetrance at Variants RET
and SEMA3 in the Combined Sample of 649 Trios
Genotype







RET rs2506030 (n ¼ 586)
AA 109 207 1.1 3 104
AG 272 273 1.9 3 104
GG 205 106 4.2 3 104
Risk allele (G) frequency 0.58 0.41 –
Allelic odds ratio 2.0
SEMA rs12707682 (n ¼ 626)
TT 266 367 1.4 3 104
CT 288 225 2.6 3 104
CC 72 34 4.3 3 104
Risk allele (C) frequency 0.35 0.23 –
Allelic odds ratio 1.8
The observed numbers of genotypes in cases and pseudo-controls are shown
with penetrance calculated under Hardy-Weinberg expectations with
pseudo-control allele frequencies and assuming a population incidence of
15/100,000 births. The allelic odds ratio is estimated from the case and
pseudo-control allele frequencies.Diversity Panel to find that the risk allele is absent only in
Oceania (Figure S2). The risk allele frequency is higher in
Asians than in Europeans, analogous to rs2435357, and
proportional to their respective disease incidence.2,4 How-
ever, unlike rs2435357, rs12707682 is as frequent in Africa
as in Asia. Consequently, given this global risk, we wished
to identify which, if any, of the class 3 Semaphorins can
lead to HSCR.
Semaphorins are transmembrane, secreted, or GPI-
linked proteins known to be involved in neuronal migra-
tion, proliferation, survival, or axonal guidance.37 We first
asked which of SEMA3A, SEMA3C, SEMA3D, and SEMA3E
are expressed in the human digestive system?We analyzed
gene expression via real-time PCR in fetal and adult mouse
and human tissues, in comparison to RET expression and
after normalization to GAPDH (MIM 138400). Impor-
tantly, signals for all four class 3 Semaphorins are present
in gut tissues, although the strongest signals are from
SEMA3A and SEMA3C and the weakest from SEMA3D
(Figure S3). All four genes produced a similar pattern of
expression in the GI tract with none mimicking RET. Simi-
larly, no clear temporal or spatial mimic was evident from
analysis of the remaining tissue panels. To determine the
in vivo spatial and temporal expression patterns during
GI tract development, we performed RNA in situ hybridiza-
tion of Sema3A, Sema3C, Sema3D, and Sema3E in the devel-
oping mouse gut relative to Ret. Ret is expressed in enteric
neural crest-derived cells (ENCCs) during phases of ENCC
migration and colonization of the developing gut and is
prominent at E11.5 (Figure 2A, Ret panel) and persists inThe Amthe ENS during later stages where it is visualized in the
myenteric plexus of the intestine, which is situated within
the outer muscular layers of the gut (Figure 2A, Ret panel).
At postnatal stages, expression of Ret persists in the myen-
teric plexus (Figure 2A, Ret panel, white arrowheads) and is
also seen in the newly forming sub-mucosal plexus
(Figure 2A, Ret panel, yellow arrowheads). Specific expres-
sion of candidate genes within the ENS can be verified
by using the Retk/k mouse strain as shown by the fact
that the ENS is absent from the intestine of these
embryos.38,39
We find that Sema3A is expressed within the developing
gut (Figure 2A, Sema3A panel, asterisk) but not within areas
that correspond to the developing ENS. In agreement with
this observation, expression of Sema3A is unchanged when
comparing wild-type and Retk/k intestines (Figure 2B,
Sema3A panel). Expression of Sema3C is detected within
a small population of ENS cells in the E15.5 gut
(Figure 2A, Sema3C panel, arrowheads) but cannot be de-
tected at the earlier or later time points (Figure 2A, Sema3C
panel). ENS expression of Sema3C at E15.5 is further
confirmed by the fact that expression is absent from the
Retk/k intestine (Figure 2B, Sema3C panel). Sema3D is
also expressed within a subset of ENCCs and can be de-
tected within the E11.5 gut (Figure 2A, Sema3D panel,
arrowheads) and persists within a subset of ENS at E15.5
and P3 (Figure 2A, Sema3D panel, arrowheads). ENS expres-
sion of Sema3D is also confirmed by the absence of expres-
sion in the Retk/k intestine (Figure 2B, Sema3D panel).
Finally, Sema3E expression is detected within the ENS
only at P3 (Figure 2A, Sema3E panel, arrowheads) and
cannot be detected at the earlier stages (Figure 2A, Sema3E
panel). Consequently, it is absent from the wild-type and
Retk/k embryos at E15.5 (Figure 2B, Sema3E panel). These
observations, in comparison to overlapping temporal and
spatial localization with Ret, suggest that Sema3d is the
best candidate for a role in HSCR with a probable role for
Sema3c as well. Although Sema3a is not expressed in the
ENS, it remains a HSCR candidate because it could affect
migration of ENCCs in the developing gut.40
To confirm the role of class 3 semaphorins in ENCC
migration, we used morpholino-based gene expression
knockdowns in zebrafish to assess whether loss of sema3c
and sema3d function also produces aganglionosis. First,
knockdown of ret in zebrafish embryos leads to a loss of
ENS neurons at 4–6 dpf, similar to that seen in the
Retk/k mouse embryos (Figures 3A, 3D, and 3E).26 Two
orthologs for SEMA3A exist in zebrafish and, therefore,
morpholinos for both were co-injected for analysis of
ENS expression. Use of 4.5 ng of each translation blocker
(one targeting sema3aa and the other targeting sema3ab)
failed to produce a loss of neurons and was indistinguish-
able from un-injected controls; similarly, injection of
4.2 ng of a translation blocker for the sole SEMA3E ortho-
log, sema3e, had no apparent effect on the ENS population
of the zebrafish gut (data not shown). Conversely, injec-
tion of morpholinos for sema3d or sema3c producederican Journal of Human Genetics 96, 581–596, April 2, 2015 587
Figure 2. Expression of Sema3A, Sema3C, Sema3D, and Sema3E in the Developing Mouse Gut
(A) RNA in situ hybridization analysis of Sema3A, Sema3C, Sema3D, and Sema3E in the developingmouse gastrointestinal tract relative to
Ret. Expression analysis is shown for Ret, Sema3A, Sema3C, Sema3D, and Sema3E in the developing gut at stage E11.5, in E15.5 intestine
sections, and in P3 intestine sections.
(B) Sema3C and Sema3D gene expression patterns in wild-type and Retk/kmutant embryos. Comparisons of Sema3A, Sema3C, Sema3D,
and Sema3E on intestinal sections from E15.5 wild-type and Retk/k mutant embryos are shown.profound effects on the zebrafish GI tract (5 dpf shown
but effects seen at all time points). A splice-blocking
morpholino for the sole SEMA3D ortholog sema3d had a
modest effect on gut innervation at a dosage of 2.1 ng
(Figure 3B) but a severe impact at twice this dosage
(Figure 3C); a similar dose effect was seen for a transla-
tion-blocking ret morpholino at 1 versus 2 ng (Figures 3D
and 3E). A translation-blocking morpholino (sema3c) for
the sole SEMA3C ortholog had a strong effect on gut inner-
vation even at a low dosage of 1.1 ng (Figure 3F). As a con-
trol, the highest tested dosages of both sema3c and sema3d
were independently co-injected with 1 ng of a morpholino
targeting p53 in an effort to counter any nonspecific
apoptosis stemming from cytotoxicity.41 Neither co-injec-
tion reversed the loss of enteric neurons (data not shown).
The gene expression studies in Ret wild-type and null
mouse embryos suggest an ENS localization for Sema3d/c
and, thus, their wild-type gene expression is contingent
on wild-type Ret function. We have previously shown, in
a HSCR mouse model, that reduced dosages of Ret and
Ednrb mutations that independently yield no enteric
phenotype do produce aganglionosis when combined in
an oligogenic mutant mouse.22,23 Consequently, we co-in-
jected morpholinos for either sema3c or sema3d together
with a ret morpholino in zebrafish embryos to test for
an analogous genetic interaction between apparently
independent pathways. Co-injection of the lower, mildly
detrimental dosages of sema3d and ret abrogated gut inner-
vation (Figures 3B, 3D, and 3G). However, co-injection of
the potent sema3c morpholino at a lower ret dosage had
no further effect on the ENS population than that medi-
ated by sema3c alone (Figures 3D, 3F, and 3H): co-injection588 The American Journal of Human Genetics 96, 581–596, April 2, 2with 2 ng of ret was required to eliminate gut innervation
(Figure 3I). These data suggest epistatic interactions be-
tween loss of function of sema3c/d and ret in zebrafish GI
tract development. Given its more profound interaction
with ret, sema3d again appears to be the most likely
HSCR candidate with a smaller effect from sema3c. These
observations are consistent with the mouse gene expres-
sion data (Figure 2).
Sequence Variants of SEMA3 in HSCR
To assess the role of class 3 Semaphorins in HSCR, beyond
the genetic association, we performed targeted next-gener-
ation sequencing of the gut-expressed SEMA3A, SEMA3C,
and SEMA3D genes in 254 diverse HSCR-affected case sub-
jects of European ancestry and identified 12 non-synony-
mous variants (Table 3, Table S3, Figure S4). Among these,
five variants in SEMA3C (p.Ser329Gly, p.Val337Met) and
SEMA3D (p.His424Gln, p.Val457Ile, p.Pro615Thr) were
selected as being likely causal based on our mouse and
zebrafish results and their locations at highly conserved
amino acid residues with their seven orthologs and seven
paralogs (SEMA3A through SEMA3G) (Figures S5 and S6).
In addition, these variants were clustered in either the
Sema or the Ig-like domain, both demonstrated to be
important for Sema structure and function, and were
located in or close to their protein interfaces, important
for Sema homo-dimerization and binding to their recep-
tors (Figures S4 and S6). We have laid greater weight on
structural conservation of class 3 Semaphorins rather
than features predicted from genomic sequence alone.
These biochemical features are, not exclusively, correlated
with the variants’ conservation (PhyloP) and predicted015
Figure 3. Synergistic Effects of Expres-
sion Knockdown of sema3c/sema3d and
ret during Zebrafish Embryogenesis
Morpholino co-knock-down of ret with in-
dividual sema3 orthologs to test for indi-
vidual and epistatic effects on the ENS
was measured at 5 dpf (days post fertiliza-
tion) by immunofluorescence using the
HuC primary antibody and an Alexa Fluor
568-tagged secondary antibody to observe
the extent of colonization by ENS neu-
rons. Asterisks denote posterior end of
gut tube, and arrows denote position of
the most posterior HuC-positive enteric
neurons. The uninjected control shows
complete colonization up to the cloacal end (A). The splice-blocking morpholino against sema3d had a modest effect on gut innervation
at a dosage of 2.1 ng (B) but a severe impact at twice this dosage (C). A similar effect can be seen for a translation-blocking morpholino
against ret at 1 (D) versus 2 (E) ng. Finally, a translation-blocking morpholino against sema3c has a strong effect on gut innervation
even at a low dosage of 1.1 ng (F). Combination of morpholinos at the lower doses of sema3d (2.1 ng) and ret (1 ng) eliminates gut
innervation (G) but required a higher dosage of ret (2 ng) when combined with sema3c (1.1 ng) to eliminate gut innervation (compare
H and I).deleterious effect (Condel) (Table 3). The five variants are
rare in public databases (NHLBI Exome Sequencing Proj-
ect, Exome Variant Server) and are generally over-repre-
sented in case subjects as compared to control subjects.
The total frequency of the five variants is 4.7%, 1.7%,
and 1.4% in S-HSCR-affected (n ¼ 95), L-HSCR/TCA-
affected (n ¼ 156), and EVS control (n ¼ 4,300) subjects,
respectively (Table 3). The ~3-fold frequency difference be-
tween S-HSCR and L-HSCR/TCA is modestly statistically
significant (p ¼ 0.039) and suggests that SEMA3C/D effects
might be primarily restricted to S-HSCR-affected case
subjects, the group in whom the genetic association was
first detected.
The reported zebrafish studies have shown genetic inter-
action between loss of function of Ret and loss of function
of Sema3c/d: we asked whether this effect is recapitulated in
HSCR. Thus, we studied the risk alleles at rs2435357,
rs2506030, and rs12707682 and all 12 identified rare cod-
ing variants at SEMA3A, SEMA3C, and SEMA3D in the 35
HSCR-affected subjects who harbored them (Table S4).
We note three features. First, HSCR-affected subjects have
a higher allele frequency of the three common alleles
even in the subset with coding variants (Table S5). Second,
rs2435357 frequency is larger for subjects with class 3 sem-
aphorin variants than in those without. Third, individuals
with rare class 3 semaphorin coding variants tend to have
specific phenotypic features: S-HSCR cases are largely sim-
plex, display no apparent parent-of-origin effect in SEMA3
variant inheritance (six inherited frommother versus eight
from father), and 25% frequency of deleterious RET coding
mutations (4 versus 12 cases have/do not have coding
mutations). In contrast, half of the L-HSCR/TCA-affected
subjects have positive familial history (9/18), a trend to-
ward maternal inheritance of SEMA3 variants (11 from
mother versus 4 from father), and a 53% frequency of dele-
terious RET codingmutations (9 versus 8 cases have/do not
have coding variants). These results are all consistent with
genetic interaction between RET and SEMA3. However,
none of these comparisons are statistically significant butThe Amthey are trends that need to be investigated in much larger
samples.
Functional Analysis of SEMA3C/3D Variants in HSCR
We investigated how the non-synonymous variants identi-
fiedmight influence class 3 Semaphorin functions, primar-
ily their effect on the stability and binding of various
SEMA3C and SEMA3D complexes. First, we examined the
predicted effects of each variant on semaphorin dimeriza-
tion or binding to plexins and neuropilins, by using
computational homology modeling, docking, and muta-
tion algorithms based on published 3D structures (Table 4,
Figure 4).28 We estimated DI_sc and DDG values that
signify the effects of the substitutions on binding and
stability of Semaphorin complexes. We find that both
p.Ser329Gly and p.Val337Met substitutions in SEMA3C
are more proximal to the Semaphorin-Semaphorin inter-
face and, hence, do not directly affect Semaphorin-Neuro-
pilin and Semaphorin-Plexin interfaces. The p.Ser329Gly
variant is found to destabilize the Semaphorin-Sema-
phorin interface as evidenced by a DI_sc of 1.158. Also,
as demonstrated by the DDG values, p.Ser329Gly mildly
decreases whereas p.Val337Met highly decreases SEMA
stability, thereby potentially indirectly influencing its
binding. Similarly, SEMA3D p.His424Gln and p.Pro615Thr
havenon-zeroDI_sc values, confirming their location at the
Semaphorin-Semaphorin interface, possibly decreasing
the binding affinity. In addition, p.His424Gln and
p.Val457Ile are found to decrease Semaphorin stability,
whereas p.Pro615Thr is found to increase Semaphorin
stability. Finally, p.His424Gln is the only substitution pre-
dicted to have a destabilizing effect on the Semaphorin-
Plexin interface.
These predictions suggested that cellular functional
analyses of these sequence variants would be instructive.
We used transient transfections of wild-type and mutant
SEMA3C/D fusion protein constructs into HEK293T cells
to measure concentrations of the secreted Sema ligands
via colorimetric assays, which were then confirmed byerican Journal of Human Genetics 96, 581–596, April 2, 2015 589
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SEMA3A E2 chr7: 83,764,220 – p.Ser54Gly 4.48 deleterious 0.0 0.7 –
SEMA3A E11 chr7: 83,634,712 rs147436181 p.Val435Ile 4.00 deleterious 1.1 1.0 1.4
SEMA3C E9 chr7: 80,430,074 rs199738991 p.Ser329Gly 2.68 neutral 0.5 0.0 0.035
SEMA3C E10 chr7: 80,427,530 rs1527482 p.Val337Met 4.55 deleterious 2.1 1.4 0.49
SEMA3D E2 chr7: 84,727,240 rs147821428 p.Ser65Pro 0.08 neutral 2.2 3.7 2.3
SEMA3D E6 chr7: 84,694,794 rs148644955 p.Thr222Ala 0.67 neutral 1.1 0.0 0.081
SEMA3D E11 chr7: 84,651,849 rs141893504 p.His424Gln 0.15 deleterious 0.5 0.0 0.52
SEMA3D E11 chr7: 84,651,752 rs142496795 p.Val457Ile 6.18 deleterious 0.5 0.0 0.012
SEMA3D E16 chr7: 84,636,183 rs117730916 p.Pro615Thr 4.60 deleterious 1.1 0.3 0.31
SEMA3D E16 chr7: 84,636,125 rs370785183 p.Arg634Gln 1.86 neutral 0.5 0.0 0.023
SEMA3D E17 chr7: 84,629,063 rs34138570 p.Ile676Thr 4.77 neutral 0.5 0.0 0.21
SEMA3D E17 chr7: 84,628,989 rs7800072 p.Lys701Gln 0.84 neutral 34.0 38.0 32.7
The table lists gene/exon name, location (hg19), dbSNP ID, amino acid substitution, conservation score (PhyloP vertebrate 46-way comparison), predicted dele-
terious effect (Condel), and variant allele frequency in S-HSCR-affected subjects (n ¼ 95), L-HSCR/TCA-affected subjects (n ¼ 156), and unaffected adult controls
(EVS, n ¼ 4,300). All comparisons are for individuals of European ancestry.immunoblotting for each of the variant proteins. Overall,
the five HSCR variants showed marked reductions in pro-
tein secretion (n ¼ 5, one-way ANOVA, p < 0.001) (Figures
5A and 5B). However, the effects were not uniform and
were significant for p.Val337Met in SEMA3C (Figure 5A)
and for p.His424Gln and p.Val457Ile in SEMA3D
(Figure 5B) with fold changes (relative to the wild-type
construct) of 0.45, 0.62, and 0.87, respectively. To further
verify these fusion protein abundance levels, equal
amounts of alkaline phosphatase (AP)-SEMA-transfected
HEK293T cells supernatant was concentrated (~25-fold)
and subjected to 7.5% SDS-PAGE. The immunoblotting
analyses confirmed the abundance level changes of each
of these variant proteins. To rule out the possibility of dif-
ferential transfection rates of the different constructs lead-
ing to fusion protein level fluctuations, we also performed
double transfections (with AP-SEMA and FLAG-Hoxb7) in
HEK293T cells and performed immunoblotting of the cell
lysate. The exposure of the same film to FLAG-antibody
and actin-antibody detected similar amounts of the
corresponding molecule, across the different parallel trans-
fections, showing transfection rates to be comparable
(Figure 5C).
Finally, we sought to test the role of the five substitutions
on the ability of SEMA3C or SEMA3D to function as a
ligand. To determine whether each variant fusion protein
could bindNeuropilin, the high-affinity obligatory binding
partner in the Semaphorin holoreceptor complex, AP-
SEMA (wild-type or variant)-containing media (quantified
bymeasuringAPactivity)was applied toCOS-7 cells overex-
pressingmouseNeuropilin1or2 (Nrp1,Nrp2).We tested all
five variants: Sema3C p.Ser329Gly did not show any effect590 The American Journal of Human Genetics 96, 581–596, April 2, 2in ligand concentration and we observed reduced binding
affinity of the cognate SEMA protein to both Nrp1 and
Nrp2, but to different extents (Figures 5D–5G). Specifically,
p.Ser329Gly and p.Val337Met in SEMA3C exhibited fold
changes in binding affinity to Nrp1 of 1.12 and 0.37
(Figure 5D); p.His424Gln, p.Val457Ile, and p.Pro615Thr
in SEMA3D showed fold changes of 0.56, 0.51, and
0.66, respectively (Figure 5E). With respect to Nrp2, these
cognate SEMA proteins displayed binding affinity changes
as of 1.18, 0.37, 0.76, 0.65, and 0.85, respectively, relative
to the wild-type construct; results shown are averages and
SEM of three independent experiments (one-way ANOVA,
***p < 0.001, **p < 0.01).
Receptors of Sema3 Proteins Are HSCR Candidates
Vertebrate Sema3 proteins are known to interact with five
specific Plexins (PlexinA1, PlexinA2, PlexinA3, PlexinA4,
and PlexinD1) and both Neuropilin1 and Neuropilin2.
To determine which of these putative Sema3 receptor com-
ponents are candidates for Sema3c and Sema3d signaling
in the ENS, we examined the expression patterns of these
genes within the embryonic mouse ENS relative to Ret.
In cross-sections of the E15.5 gut, expression of Ret is
observed in a nearly complete ring in the outer layers
of the intestine (Figure 6A). High-magnification view of
this myenteric region shows clear expression of Ret in indi-
vidual ENS neurons (Figure 6B, Ret panel). In Retk/k gut
sections, which lack ENS cells, Ret expression is absent
(Figure 6B, Ret panel). Analysis of Plexin and Neuropilin
expression patterns (Figures 6B and 6C; Wild-type
panels) shows that most of the known Sema3 receptor
components, PlexinA1-A4 and Neuropilin1-2 (Nrp1, 2), are015
Table 4. Predicted Effects of Substitutions on the Stability and Binding of Semaphorin Complexes
Substitution
Sema-Sema Complex Sema-Neuropilin Complex Sema-Plexin Complex
DI_sc DDG DI_sc DDG DI_sc DDG
Sema3C: p.Ser329Gly 1.158 5.986 0 1.974 0 1.974
Sema3C: p.Val337Met 0 30.256 0 15.067 0 15.067
Sema3D: p.His424Gln 0.005 5.038 0 2.420 0.023 2.592
Sema3D: p.Val457Ile 0 0.613 0 0.305 0 0.305
Sema3D: p.Pro615Thr 0.002 92.941 0 46.458 0 46.458
The change in the free energy upon substitution (DDG¼DGvariant –DGwild-type) calculated via the standard Rosetta energy function estimates the variant’s effect on
stability of the Semaphorin complexes. The change in the interface score upon substitution (DI_sc¼ I_scvariant – I_scwild-type) predicts the variant’s effect on binding
between semaphorins and neuropilins or plexins, respectively. All free energies are listed in Rosetta Energy Units (REU).expressed in the ENS. An absence of corresponding expres-
sion patterns in the Retk/k gut enables us to confirm that
the wild-type expression domains are within the ENS (Fig-
ures 6B and 6C; Retk/k panels). In contrast, although
PlexinD1 is expressed broadly within the gut, it does not
appear to be expressed in the ENS (Figure 6C; Wild-type
panel). Consistent with this observation, the pattern
of PlexinD1 appears unchanged in Retk/k gut sections
(Figure 6C; Retk/k panel). We observe Nrp2 expression
within the ENS in contrast to a previously published study
gut.40 We note, however, that Nrp2 expression in that
study used a gene-trap reporter, rather than direct detec-
tion of RNA or protein, and that independent analysis
from the GenePaint and Eurexpress gene expression data-
bases also show ENS expression of Nrp2. Given the fact
that Semaphorin receptor components are expressed in
the ENS, they too are candidate genes for HSCR.Discussion
Major mutations leading to HSCR are invariably in genes,
expressed in neuroblasts or mesenchymal cells, involved
in the earliest stages of fate determination of ENCCs and
their subsequent survival, proliferation, migration, and
differentiation.1–3,42 These include components of the
RET signaling pathway, affecting their migration down
the GI tract via a GDNF gradient, and the EDNRB signaling
pathway, modulating migration as well as proliferation
through EDN3-mediated inhibition of differentiation.
Regulating these genes are three major transcription fac-
tors, SOX10, PHOX2B, and ZEB2, influencing the timing,
migration, and survival of ENCCs.42 It is, therefore, unsur-
prising that deleterious heterozygous mutations in these
genes have high penetrance for HSCR or result in syn-
dromic forms, being early developmental blocks in the
ENS. What is remarkable is that a large majority (79%) of
HSCR-affected individuals have a low-penetrance RET
enhancer mutation.6 Studies described here have now
identified a second such RET variant, suggesting that
reduced RET function is necessary but might not be suffi-
cient for aganglionosis. Therefore, we hypothesize thatThe Amclinical disease occurs only when pathways additional to
RET also have compromised function. We have previously
shown that coordinate loss of function of RET and EDNRB
contributes to human disease and recapitulates aganglio-
nosis in a mouse model.22,23 We now demonstrate that
loss-of-function genetic defects in SEMA3C/D are an addi-
tional major pathway in HSCR and ENS development.
Class 3 Semaphorins are secreted glycoproteins that
signal through neuropilin and plexin receptors and
contain a ~400 amino acid ‘‘Sema,’’ a cysteine-rich PSI
(plexins, semaphorins, and integrins), and a C2 type
immunoglobulin (IG) domain.43 Although initially char-
acterized as neuronal guidance cues, signaling of sema-
phorin ligands is now known to be major contributors to
homeostasis and morphogenesis of many tissues and is
widely studied for its role in cell migration, proliferation,
and survival, neuronal connectivity, and cardiac develop-
ment.44–46 Sema3s are the only vertebrate-secreted sema-
phorins and consist of seven family members, SEMA3A
through SEMA3G. Their obligate co-receptors are Neuropi-
lin1 or Neuropilin2, which, together with a Plexin receptor
(PlexinA1 through PlexinA4, PlexinD1), form an active
holoreceptor complex for most Sema3s to transduce
biochemical responses in distinct neuronal subtypes.47
The studies described here clearly demonstrate that
Sema3s, and perhaps their cognate receptors, have signifi-
cant roles in ENS development.
We have provided three pieces of information that
demonstrate a specific role of SEMA3C/D in HSCR: (1) map-
ping of a common susceptibility allele adjacent to SEMA3D
and identification of rare hypomorphic mutations in
affected individuals, (2) their gene expression in the hu-
man, mouse, and zebrafish GI tract and specifically the
ENS, and (3) the synergistic effect of Ret and Sema3c/d
loss of function on aganglionosis in model systems. A pre-
vious RNA microarray study compared gene expression in
wild-type and Retk/kmouse GI tracts and identified three
ENS-localized genes that are semaphorin signaling compo-
nents: Crmp1, Dpysl3 (Crmp4), and Nrp1.48 These data add
to the importance of SEMA3D signaling in the ENS since in
zebrafish, sema3d has been shown to mediate repulsive
cues for axonal guidance through binding with nrp1a, anerican Journal of Human Genetics 96, 581–596, April 2, 2015 591
Figure 4. In Silico Modeling of Semaphorin3 with Their Neuropilin and Plexin Complexes
Models of the Sema3C/Neuropilin1/PlexinA2 (A, B, C) and Sema3D/Neuropilin1/PlexinA2 (D, E, F) complexes in top view (A, D), side
view (B, E), and front view (C, F) are shown, with the Sema3 protomers colored in cyan, Neuropilin1 in golden brown, and PlexinA2 in
green. The five residues variant in HSCR-affected subjects are colored (yellow for Ser329 andmagenta for Val337 in Sema3C; dark blue for
His424, magenta for Val457, and yellow for Pro615 in Sema3D) for visualization.ortholog of Nrp1,49 and acts synergistically with dpysl3 to
promote peripheral axon outgrowth.50 Other class 3 Sem-
aphorins might also have a role in the GI tract; Sema3a
has previously been shown to be expressed in the chick
rectal wall,51 and in the mouse hindgut mesenchyme.40
In contrast, our results do not confirm a role for Sema3a
or Sema3e in the ENS but they might have indirect roles.
Mice lacking Sema3a display premature entry of sacral
enteric neural precursors (ENPs) into the distal hindgut,
indicating a potential repulsive role. However, the contri-
bution of sacral ENPs to the ENS is small; the largest contri-
bution comes from vagal ENPs, and although Sema3a is
highly expressed in themouse caecum andmigrating vagal
ENPs express Nrp1, there is no effect on the timing or
magnitude of ENS colonization by this population in
Sema3a/ mice.40 The possibility exists, to the contrary,
that it is Sema3d that exerts an influence on vagal ENPs
via Nrp1. The Sema3d knockout mouse has yet to be exam-
ined for ENS defects and our genetic interaction data sug-
gest that these defects might manifest in Sema3d mutant
mice only with concomitant Ret loss of function.
The mechanism of action of Sema3c/d in the ENS is un-
known but both have been implicated in patterning de-
fects during heart development, a not-infrequent feature
of HSCR.2,3 First, Sema3cmutant mice die within hours af-
ter birth from interruption of the aortic arch and improper
septation of the cardiac outflow tract; Sema3dmutant mice
have anomalous pulmonary venous connections and a
SEMA3D p.Pro615Thr variant, identical to one we identi-
fied in this study, has been reported in a case with total
anomalous pulmonary venous connection.52,53 In both in-
stances, wild-type semaphorins appear to establish bound-
aries for stereotypical neural crest cell migration in the592 The American Journal of Human Genetics 96, 581–596, April 2, 2developing heart. We hypothesize that an identical func-
tion is served in GI tract development. One attractive hy-
pothesis is that class 3 Semaphorins are synthesized and
secreted into the gut mesenchyme and form an appro-
priate gradient across the gut radius. Because ENCCs in
the embryonic gut express plexins and neuropilins, bind-
ing of Sema3c/Sema3d to the receptor complex could
function as a signal to promote the migratory behavior
of neurons, as observed for other semaphorin family
members.54 These axon guidance cues might also exert
long-range regulation of neural connectivity and synaptic
specificity.55
Beyond deciphering the developmental mechanisms
that are compromised in HSCR by class 3 Semaphorin mu-
tations, numerous genetic questions remain. First, what
are the molecular identities of the polymorphic SEMA3
and RET susceptibility alleles? Are they transcriptional en-
hancers, like the intron 1 RET element, and if so which
transcriptional regulators bind them? It is most likely
that the risk allele at rs2506030 affects RET. But, does the
risk allele at rs12707682 control expression of SEMA3D
~182 kb away or SEMA3C that is ~4Mb away, or both? Reg-
ulatory cis-elements routinely act over significant dis-
tances (R100 kb) from their cognate promoters, with
several operating over distances ~1 Mb.56 Consequently,
gene expression studies in the GI tract of HSCR-affected
individuals with known genotypes of rs12707682 are
needed to resolve this question. Because the defect is dur-
ing development, providing these answers will require
studies in cellular and animal models of this variant.
Finally, our human genetic data do predict some of its
properties that are relevant to the genetic counseling of
HSCR: the risk allele is more prevalent in males than015
Figure 5. AP-SEMA Fusion Protein Accumulation and Receptor Binding
(A–C) Secreted SEMA ligand concentrations were determined by measuring alkaline phosphatase (AP) activity for SEMA3C (A) and
SEMA3D (B); results are shown as fold change relative to the wild-type construct and error bars represent SEM. The upper bands in
(A) (for SEMA3C) and (B) (for SEMA3D) represent the AP-SEMA fusion protein of predicted molecular weight (MW) of ~130 kDa; the
lower bands of ~90 kDa are suspected to be an abundant albumin within the medium recognized by the antibody and used as loading
control. An additional band (arrowhead) was detected in only the pAPTag4 transfected supernatant at ~63 kDa, indicating the expression
of AP (MW 67 kDa) upon empty vector transfection. Mock represents conditioned medium from untransfected HEK293T cells; pAPTag4
represents the empty vector transfection. To test the transfection rate, double-transfection with AP-SEMA and FLAG-Hoxb7 on HEK293T
cells followed by immunoblotting is presented in (C).
(legend continued on next page)
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Figure 6. Analysis of Gene Expression of PlexinA1, Plexin A2, Plex-
inA3, Plexin A4, PlexinD1, Neuropilin1, and Neuropilin2 Relative to
Ret in the E15.5 Mouse Wild-Type and Ret Mutant Gut
RNA in situ hybridization analysis was performed for all probes on
E15.5 intestine tissue cross sections from both wild-type embryos
and Retk/k mutant embryos. Ret is expressed in enteric neurons
in the myenteric plexus in the outer regions of the E15.5 intestine
(A, lumen denoted by asterisk). High-magnification view of boxed
area of (A) is shown in (B), revealing individual Ret-expressing
enteric neurons in the myenteric plexus (B, Ret panel, arrow). Ret
expression is absent in corresponding cross-sections in Retk/k in-
testine tissue, which lack ENS neurons (B, Ret panel). PlexinA1 is
expressed in population of ENS cells (B, Plxna1 panel, arrow),
and this expression is absent in Retk/k gut tissues (B, Plxna1
panel), thus confirming that the expression observed in wild-
type tissue corresponds to ENS expression. Expression of PlexinA2,
PlexinA3, and PlexinA4 is also observed in ENS cells (B and C,
Plxna2, Plxna3, Plxna4 panels, arrows), and expression is not
detectable in Retk/k gut tissues (B and C, Plxna2, Plxna3, Plxna4
panels). PlexinD1 has widespread expression within the gut, but
not, apparently, within the ENS (C, Plxnd1 panel). Consistent
with this observation, the expression profile appears unchanged
in Retk/k gut tissues (C, Plxnd1 panel). Populations of the ENS
do express Neuropilin1 and Neuropilin2 (C, Nrp1, Nrp2 panels,
arrows), and this expression is not observed in Retk/k gut tissues
(C, Nrp1, Nrp2 panels).females, simplex than multiplex cases, and in S-HSCR as
compared L-HSCR/TCA, although none of these effects
are significant. This difference between the phenotypic as-
sociations of rs12707682 and rs2435757 could be due
either to a smaller effect, and consequent lower statistical
power, of the SEMA3 variants or to an effect restricted to
only some genes (e.g., RET) owing to their molecular prop-
erties (e.g., sex differences in gene expression). We now
know of four such non-coding but highly polymorphic al-
leles, two at RET and one each at NRG1 and SEMA3C/D,
the latter two interacting with RET. This is surprising for(D and E) AP-SEMA binding affinity with Neuropilin1. COS-7 cell
Sema3D- (E) containing medium. Enzymatic detection of binding in
fected cells but to different extents (scale bars represent 50 mm). Qua
COS-7 cells were conducted. Results shown are bound AP activity av
(F and G) AP-SEMA binding affinity with Neuropilin2. Legend is the
594 The American Journal of Human Genetics 96, 581–596, April 2, 2a rare multifactorial developmental disorder and begs the
question of how many such common HSCR susceptibility
alleles exist. We suspect that a focused search of ENS-
localized and GI-tract mesenchymal genes can identify
additional common variants that, together with rare dele-
terious alleles, will complete the molecular disease archi-
tecture of HSCR.Accession Numbers
The NCBI dbSNP accession number for the novel variant listed in
Table 3 is ss1582838823, scheduled to appear in the next dbSNP
build (B144), planned for fall 2015.Supplemental Data
Supplemental Data include six figures and five tables and can be
found with this article online at http://dx.doi.org/10.1016/j.
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